Home > Riviste > Minerva Obstetrics and Gynecology > Fascicoli precedenti > Articles online first > Minerva Obstetrics and Gynecology 2021 Jul 30

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Obstetrics and Gynecology 2021 Jul 30

DOI: 10.23736/S2724-606X.21.04805-3

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Preimplantation genetic testing in assisted reproduction

José I. MADERO 1 , María C. MANOTAS 1, 2 , Mary GARCÍA-ACERO 1, 2 ,Andrea LÓPEZ-CÁCERES 1, Claudia LÓPEZ JAIMES 1

1 Clínica EUGIN, Bogotá, Colombia; 2 Institute of Human Genetics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia


PDF


In the last years technologies, have been developed that allow obtaining genetic information in less time and at lower cost, revolutionizing the genetic diagnosis in reproductive medicine, with availability of genetic tests from conception. High throughput sequencing analyzes have increased the ability to detect embryos with genetic diseases, which has contributed to the better selection of embryos for in vitro fertilization and, therefore, better reproductive outcomes. The preimplantation genetic testing (PGT) includes three sub-categories of PGT for aneuploidies (PGTA), PGT for single gene / monogenic disorders (PGT-M), and PGT for chromosome structural rearrangements (PGT-SR). This review provides an overview of the evolution of preimplantation genetic testing, the advantages and disadvantages of these technologies and their applicability in reproductive medicine as well as a description the legislation and bioethics aspects. Advances in preimplantation genetic testing are changing clinical practice, pose new challenges for genetic counseling and alternative plausible to substantially reduce the risk of an adverse reproductive outcome related to the transfer of abnormal embryos. Despite the overall important implantation rates achieved following transfer of euploid embryos, PGT-A did not improve overall pregnancy outcomes in all women. There is a definite need for studies to identify the causes of why not all euploid embryos implant. Also, debate continues regarding the accuracy and the safety of this approach and the currently available evidence is insufficient to support PGT-A in routine clinical practice. The general recommendation is that PGT-A, PGT-M and PGT-SR should be guided according to the antecedents of the couples.


KEY WORDS: Preimplantation genetic testing; PGT-A; Assisted reproduction; Embryo cfDNA; Non-invasive PGT-A; Embryo aneuploidy testing; Spent Blastocyst media; IVF

inizio pagina